NCT04384367View on ClinicalTrials.gov

Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine

PHASE3CompletedINTERVENTIONAL
Enrollment

2,068

Participants

Timeline

Start Date

December 30, 2022

Primary Completion Date

October 30, 2024

Study Completion Date

November 30, 2024

Conditions
Migraine
Interventions
DRUG

Rizatriptan 10 mg + Naproxen 550mg

oral - single dose

DRUG

Maxalt 10Mg Tablet

oral - single dose

DRUG

Flanax 550mg

oral - single dose

DRUG

Placebo oral tablet

oral - single dose

Trial Locations (2)

06696-000

Eurofarma Laboratorios S.A, São Paulo

Unknown

CEPIC, São Paulo

Sponsors
All Listed Sponsors
lead

Eurofarma Laboratorios S.A.

INDUSTRY